Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Bevacizumab 32Cetuximab 28Fluorouracil 26Leucovorin 24Specimen Handling 23Oxaliplatin 23pembrolizumab 18Biopsy 16Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 9atezolizumab 7Folfox protocol 7fludarabine 6balstilimab 6Pemetrexed 6Panitumumab 6Cyclophosphamide 6Cisplatin 6Carboplatin 6Capecitabine 6trifluridine tipiracil drug combination 5encorafenib 5Standard of Care 5IFL protocol 5HMPL-013 5Gemcitabine 5dehydroftorafur 4Immunoglobulin G 4Disulfides 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × berzosertib × 30 days × Clear all
NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡